International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 14 Issue 2, April-June, Pages:37-47

Functional Outcome of Total Hip Arthroplasty in Steroid-Induced Avascular Necrosis Among COVID-Recovered Patients

Dr V Ratan Singh Naik, Dr Sandeep Saraf and Dr Krishna Agarwal

Osteonecrosis or Avascular Necrosis (AVN) of the femoral head is a disabling condition in young individuals. The number of cases has significantly increased after the COVID-19 pandemic. The use of corticosteroids in treating COVID-19 may have contributed to the developing of AVN in young patients. Aggressive presentation and rapid progression of osteonecrosis have been implicated as risk factors for total hip arthroplasty. Early management of osteonecrosis of the femoral head (ONFH) entails joint preservation procedures, antiresorptive therapy, and reduced weight bearing. THR should be performed only as a last resort due to the aggressive progression of ONFH to severe and incapacitating osteoarthritis. There is a definite risk of contralateral hip affection, and the pathophysiology of varying affections is still unclear. Due to the early presentation and young age of patients at the time of surgery, there is a need for continuous monitoring. Hence there is a need for continuous research in this area. The study aims to know the effectiveness of total hip replacement (THR) for femoral head osteonecrosis among COVID-19-affected patients. Objectives are to identify symptomatology, limitation of functional hip range of movements, plain radiography findings, Ficat -Arlet staging, and to determine the functional outcome following THR by quantification through mean VAS score and modified-HHS score. The key findings of our study are A) there is a steady risk of progression of AVN to secondary osteoarthritis, which entails the need for THA, B) In unilateral involvement, with no affection in the uninvolved hip (nascent hip) at the initial presentation the disease does not progress, whereas those involved hips with low-grade AVN can progress to Highgrade C) There is a greater acceptability of THR as a definitive procedure with good to excellent functional outcome.

Keywords: Avascular necrosis, COVID-19, Femoral head, Osteonecrosis, Steroids, Total Hip Replacement
Full HTML:
  1. Birla V, Vaish A, Vaishya R. Risk factors and pathogenesis of steroid-induced femoral head osteonecrosis – A scoping review. J Clin Orthop Trauma. 2021 Oct 13;23:101643. doi 10.1016/j.jcot.2021.101643, PMID 34722150, PMCID PMC8531658.
  2. Hall AJ, Clement ND, IMPACT Revisited Group, MacLullich AMJ, White TO, Duckworth AD. COVID-19 during the index hospital admission confers a 'double-hit' effect on hip fracture patients and is associated with a two-fold increase in 1-year mortality risk. Musculoskeletal Care. 2022 Sep;20(3):705-17. doi 10.1002/msc.1674. PMID 35929286, PMCID PMC9538200.
  3. Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: a meta-analysis and systematic literature review. J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. doi 10.1016/j.arth.2015.03.036. PMID 25900167, PMCID PMC7127809.
  4. Dhanasekararaja P, Soundarrajan D, Kumar KS, Pushpa BT, Rajkumar N, Rajasekaran S. Aggressive presentation and rapid progression of osteonecrosis of the femoral head after COVID-19. Indian J Orthop. 2022 Apr 25;56(7):1259-67. doi: 10.1007/s43465-022-00635-2, PMID 35495964, PMCID PMC9037053.
  5. Leung TYM, Chan AYL, Chan EW, Chan VKY, Chui CSL, Cowling BJ, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020 Dec;9(1):2190-9. doi: 10.1080/22221751.2020.1825914, PMID 32940572, PMCID PMC7586446.
  6. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct;32(2):94-124. doi 10.1053/sarh.2002.33724b, PMID 12430099.
  7. Anderton JM, Helm R. Multiple joint osteonecroses following short-term steroid therapy. Case report. J Bone Joint Surg Am. 1982 Jan;64(1):139-41. doi: 10.2106/00004623-198264010-00020, PMID 7054196.
  8. Liu LH, Zhang QY, Sun W, Li ZR, Gao FQ. Corticosteroid-induced osteonecrosis of the femoral head: detection, diagnosis, and treatment in earlier stages. Chin Med J (Engl). 2017 Nov 5;130(21):2601-7. doi 10.4103/0366-6999.217094, PMID 29067959, PMCID PMC5678261.
  9. Chacko A, Babu M, Thomas DK. Osteonecrosis of the bilateral femoral head in a post-COVID-19 patient: a case report. Int J Res Orthop. 2021;7(3):674-8. doi: 10.18203/issn.2455-4510.IntJResOrthop20211630.
  10. Li W, Huang Z, Tan B, Chen G, Li X, Xiong K, et al. The general recommendation for assessing and managing the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19. J Orthop Translat. 2021 Nov;31:1-9. doi: 10.1016/ PMID 34692412, PMCID PMC8526281.
  11. Väänänen M, Tervonen O, Nevalainen MT. Magnetic resonance imaging of avascular necrosis of the femoral head: predictive findings of total hip arthroplasty. Acta Radiol Open. 2021 Apr 27;10(4):20584601211008379. doi 10.1177/20584601211008379, PMID 35140984, PMCID PMC8819766.
  12. Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: current concepts. Indian J Orthop. 2015 Jan-Feb;49(1):28-45. doi 10.4103/0019-5413.143911, PMID 25593355, PMCID PMC4292325.
  13. Hart A, Janz V, Trousdale RT, Sierra RJ, Berry DJ, Abdel MP. Long-term survivorship of total hip arthroplasty with highly cross-linked polyethylene for osteonecrosis. J Bone Joint Surg Am. 2019 Sep 4;101(17):1563-8. doi 10.2106/JBJS.18.01218, PMID 31483399.
  14. Liu N, Zheng C, Wang Q, Huang Z. Treatment of non-traumatic avascular necrosis of the femoral head (Review) [review]. Exp Ther Med. 2022 May;23(5):321. doi 10.3892/etm.2022.11250. PMID 35386618, PMCID PMC8972838.
  15. Rajpura A, Wright AC, Board TN. Medical management of osteonecrosis of the hip: a review. Hip Int. 2011;21(4):385-92. doi 10.5301/HIP.2011.8538, PMID 21786259.
  16. Guo P, Gao F, Wang Y, Zhang Z, Sun W, Jiang B, et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. Med (Baltim). 2017 Apr;96(16):e6646. doi 10.1097/MD.0000000000006646, PMID 28422866, PMCID PMC5406082.
  17. Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: current concepts. Indian J Orthop. 2015;49(1):28-45. doi: 10.4103/0019-5413.143911, PMID 25593355.
  18. Vishwanathan K, Akbari K, Patel AJ. Is the modified Harris hip score a valid and responsive instrument for outcome assessment in the Indian population with pertrochanteric fractures? J Orthop. 2018 Jan 3;15(1):40-6. doi 10.1016/j.jor.2017.12.001, PMID 29326497, PMCID PMC5760250.
  19. Ergözen S, Kaya E. Avascular necrosis due to corticosteroid therapy in COVID-19 as a SYNDEMIC. CAJMHE. 2021;2(2):91-5. doi: 10.47316/cajmhe.2021.2.2.03.
  20. Kakaria HL, Sharma AK, Sebastian B. Total hip replacement in avascular necrosis of femoral head. Med J Armed Forces India. 2005 Jan;61(1):33-5. doi: 10.1016/S0377-1237(05)80115-7. PMID 27407701, PMCID PMC4923353.
  21. Banerjee I, Robinson J, Sathian B. Corticosteroid induced avascular necrosis and COVID-19: the drug dilemma. Nepal J Epidemiol. 2021 Sep 30;11(3):1049-52. doi: 10.3126/nje.v11i3.39309. PMID 34733566, PMCID PMC8560140.
  22. Agarwala SR, Vijayvargiya M, Pandey P. Avascular necrosis as a part of ’long COVID-19’. BMJ Case Rep. 2021 Jul 2;14(7):e242101. doi: 10.1136/bcr-2021-242101, PMID 34215639, PMCID PMC8256728.
  23. Koutalos AA, Stefanou N, Malizos KN. Postacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked. Int J Infect Dis. 2022 Aug;121:11-3. doi: 10.1016/j.ijid.2022.04.026. PMID 35462037, PMCID PMC9022373.
  24. Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health. 2021 Jun;14(6):740-8. doi: 10.1016/j.jiph.2021.03.015. PMID 34020215, PMCID PMC8056786.
  25. Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid-induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev. 2010 Sep;9(11):721-43. doi: 10.1016/j.autrev.2010.06.007. PMID 20621176, PMCID PMC7105235.
  26. McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ. 2001 Jan 23;164(2):205-6. PMID 11332313, PMCID PMC80680.
  27. Shigemura T, Nakamura J, Kishida S, Harada Y, Ohtori S, Kamikawa K et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatol (Oxf Engl). 2011 Nov;50(11):2023-8. doi 10.1093/rheumatology/ker277. PMID 21865285.
  28. Krez A, Lane J, Heilbronner A, Park-Min KH, Kaneko K, Pannellini T, et al. Risk factors for multi-joint disease in patients with glucocorticoid-induced osteonecrosis. Osteoporos Int. 2021 Oct;32(10):2095-103. doi: 10.1007/s00198-021-05947-x. PMID 33877383, PMCID PMC8056829.
  29. Suksathien Y, Sueajui J. Mid-term results of short stem total hip arthroplasty in patients with femoral head osteonecrosis. Hip Int. 2019 Nov;29(6):603-8. doi 10.1177/1120700018816011. PMID 30526072.
  30. Burahee AS, Barry VE, Sutcliffe RP, Mahroof S. Older patients with proximal femur fractures and SARS-CoV-2 infection - an observational study. SICOT J. 2021;7:5. doi: 10.1051/sicotj/2021001, PMID 33595434.
  31. Phruetthiphat OA, Sangthumprateep V, Trakulngernthai S, Aegakkatajit N, Chotanaphuti T, Chanpoo M. Functional outcome and complication following THA through modified direct anterior approach correlated to cadaveric study: are there any differences in Asian hip? J Orthop Surg Res. 2021 Aug 20;16(1):513. doi: 10.1186/s13018-021-02661-6, PMID 34416884, PMCID PMC8377820.
  32. Luthra JS, Al Riyami A, Allami MK. Dual mobility total hip replacement in a high-risk population. SICOT J. 2016;2:43. doi: 10.1051/sicotj/2016037. PMID 27924742, PMCID PMC5142081.
[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions